EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vistagen Therapeutics's enterprise value is $5.96 Mil.
Vistagen Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-33.19 Mil. Therefore, Vistagen Therapeutics's EV-to-EBITDA for today is -0.18.
The historical rank and industry rank for Vistagen Therapeutics's EV-to-EBITDA or its related term are showing as below:
VTGN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.04 Med: -1.05 Max: 0.31
Current: -0.18
During the past 13 years, the highest EV-to-EBITDA of Vistagen Therapeutics was 0.31. The lowest was -25.04. And the median was -1.05.
VTGN's EV-to-EBITDA is ranked worse than 100% of 473
companies
in the Biotechnology industry
Industry Median: 9.22
vs VTGN: -0.18
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-25), Vistagen Therapeutics's stock price is $4.72.
Vistagen Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.509. Therefore, Vistagen Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Vistagen Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Vistagen Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vistagen Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Vistagen Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistagen Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vistagen Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vistagen Therapeutics's EV-to-EBITDA falls into.
Vistagen Therapeutics EV-to-EBITDA Calculation
Vistagen Therapeutics's EV-to-EBITDA for today is calculated as:
Vistagen Therapeutics's current Enterprise Value is $5.96 Mil.
Vistagen Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Vistagen Therapeutics's PE Ratio for today is calculated as:
Vistagen Therapeutics's share price for today is $4.72.
Vistagen Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.509.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Vistagen Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Vistagen Therapeutics (Vistagen Therapeutics) Business Description
Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. The portfolio of the company includes PH94B, a novel neuroactive nasal spray; PH10, an odorless, fast-acting synthetic neurosteroid and AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR) which is the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VTGN has been successfully added to your 